Oral Biologics & Biosimilar Drugs Global Market Report 2022 by The Business Research Company is the most comprehensive report available on the market, being wide-ranging both in terms of chronology and geography. It covers the historic period – 2016-2021, and the forecast period – 2022-2026, with additional forecasts for 2026-2031. The report helps gain a truly global perspective as it covers 60 geographies, focusing on major economies in each region – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
TBRC’s market report includes a chapter on the COVID-19 impact on the oral biologics & biosimilar drugs industry, which gives valuable insights on supply chain disruptions, logistical challenges, and other economic implications of the virus on the market and how companies can strategize to bounce back from it. With updated market numbers according to the effects of the coronavirus, the report provides the most accurate expected oral biologics & biosimilar drugs market growth numbers from 2022-2031.
Request a Sample of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3792&type=smp
The global oral biologics & biosimilar drugs market size is expected to grow from $4.06 billion in 2021 to $4.91 billion in 2022 at a compound annual growth rate (CAGR) of 21%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The oral biologics and biosimilar drugs market is expected to reach $10.41 billion in 2026 at a CAGR of 20.7%.
View more on the report:
The Oral Biologics & Biosimilar Drugs Global Market Report 2022-31 by The Business Research Company evaluates oral biologics & biosimilar drugs market size, growth rate, drivers, oral biologics & biosimilar drugs industry trends, and major companies.
The oral biologics & biosimilar drugs market segments in the report are:
1) By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors
2) By Disease: Asthma, Crohn’s Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Others
3) By Molecule Type: Vaccines, Proteins & Peptides, Monoclonal Antibodies, Others
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The table of contents in TBRC’s oral biologics & biosimilar drugs market report includes:
Table Of Contents
- Executive Summary
- Oral Biologics & Biosimilars Market Characteristics
- Oral Biologics & Biosimilars Market Trends And Strategies
- Impact Of COVID-19 On Oral Biologics & Biosimilars
- Oral Biologics & Biosimilars Market Size And Growth
- Oral Biologics & Biosimilars Market Segmentation
- Oral Biologics & Biosimilars Market Regional And Country Analysis
.
.
.
- Oral Biologics & Biosimilars Pipeline Analysis
- Key Mergers And Acquisitions In The Oral Biologics & Biosimilars Market
- Oral Biologics & Biosimilars Market Future Outlook and Potential Analysis
List Of Tables
Table 1: Global Historic Market Growth, 2016-2021, $ Billion
Table 2: Global Forecast Market Growth, 2021-2026F, 2031F, $ Billion
Table 3: Global Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
Table 4: Global Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
Table 5: Global Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
……….
Table 28: Novartis Financial Performance
Table 29: Rani Therapeutics Financial Performance
Table 30: Eli Lilly and Co. Financial Performance
Table 31: AstraZeneca plc Financial Performance
Table 32: Novo Nordisk A/S Financial Performance
Here is a list of similar reports by The Business Research Company:
Tumor Ablation Therapy Devices
Biosimilar Monoclonal Antibodies
About The Business Research Company:
The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology. It has offices in the UK, the US and India and a network of trained researchers in 20+ countries globally.
Get a quick glimpse of our services here:
https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Contact Information:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
Follow us on Twitter: https://twitter.com/tbrc_info
Check out our Blog: http://blog.tbrc.info/
